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The human brain generally remains structurally and functionally sound for many decades, despite the
post-mitotic and non-regenerative nature of neurons. This is testament to the brain’s profound capacity
for homeostasis: both neurons and glia have in-built mechanisms that enable them to mount adaptive or
protective responses to potentially challenging situations, ensuring that cellular viability and function-
ality is maintained. The high and variable metabolic and mitochondrial activity of neurons places several
demands on the brain, including the task of neutralizing the associated reactive oxygen species (ROS)
produced, to limit the accumulation of oxidative damage. Astrocytes play a key role in providing anti-
oxidant support to nearby neurons, and redox regulation of the astrocytic Nrf2 pathway represents a
powerful homeostatic regulator of the large cohort of Nrf2-regulated antioxidant genes that they express.
In contrast, the Nrf2 pathway is weak in neurons, robbing them of this particular homeostatic device.
However, many neuronal antioxidant genes are controlled by synaptic activity, enabling activity-de-
pendent increases in ROS production to be offset by enhanced antioxidant capacity of both glutathione
and thioredoxin-peroxiredoxin systems. These distinct homeostatic mechanisms in neurons and astro-
cytes together combine to promote neuronal resistance to oxidative insults. Future investigations into
signaling between distinct cell types within the neuro-glial unit are likely to uncover further mechanisms
underlying redox homeostasis in the brain.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The post-mitotic and non-regenerative nature of neurons
means that either excessive oxidative damage needs to be avoided,
or if possible reversed when it happens. Despite the well-docu-
mented increase in neuronal oxidative damage in the ageing brain,
and the association of oxidative stress with several neurodegen-
erative disorders, the longevity of mammalian (particularly pri-
mate) neurons reﬂects successful redox homeostasis over many
years. Understanding the basis for this illuminates a fundamental
part of brain metabolism, points to key control nodes that may go
wrong in disease, and also provides potential therapeutic targets
for disorders associated with oxidative stress. The systems used
inside the brain for neutralization of ROS or electrophilic xeno-
biotics are similar to those outside: the glutathione system,
thioredoxin/peroxiredoxin system, superoxide dismutases, and
catalase all play key roles in ROS neutralization and xeniobiotic
adduction [1], and will be familiar to readers of this journal.
Many antioxidant genes in the systems outlined above arer Inc. This is an open access article
Hardingham).under the control of a master regulator of antioxidant defences,
the transcription factor Nrf2, which binds to a promoter element
called the antioxidant response element (ARE) present on these
genes. Nrf2 is normally targeted for ubiquitin-mediated degrada-
tion by its endogenous inhibitor Keap1 [2,3]. However, under
conditions of redox imbalance, oxidative modiﬁcation of Keap1
inhibits the Nrf2 degradation process, leading to Nrf2 accumula-
tion in the nucleus, and the induction of ARE-containing genes [2–
4]. By promoting ROS neutralization, xenobiotic clearance, and
dampening inﬂammation, Nrf2 promotes cytoprotection in a
variety of stress-related disorders affecting many tissues in the
body, and is also anti-tumourigenic [3,4]. There is also growing
evidence that Nrf2 controls mitochondrial function directly by
inﬂuencing fatty acid oxidation, respiratory substrate availability
and ATP synthesis, as well as acting upstream to regulate mi-
tochondrial ROS production [5,6]. As such, the Keap1/Nrf2 system
is an ideal homeostatic regulator of intrinsic cellular antioxidant
defences and mitochondrial health. Moreover, the fact that Keap1-
mediated Nrf2 degradation can be inhibited by a variety of elec-
trophilic small molecules makes it a therapeutically attractive
pathway for a variety of disorders [7]. Shortly after landmark
discoveries by the Yamamoto laboratory regarding the role of Nrf2
and Keap1 in regulating ARE-containing genes [8,9], interest beganunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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this was driven by the laboratories of Jeff Johnson and Tim Murphy
who found that Nrf2 had very different activities between neurons
and astrocytes, and that Nrf2-mediated cytoprotective effects can
be affected in a non cell-autonomous manner [10,11]. This review
will describe the very different roles of the Nrf2 pathway in neu-
rons and astrocytes, and how Nrf2-dependent and -independent
transcriptional programs in different cell types cooperate to pro-
mote redox homeostasis in the brain.
2. The Nrf2 pathway is weak in forebrain neurons
The ﬁrst indication that the Nrf2-ARE pathway was particularly
weak in neurons came from a study in neuronal and glial cells
from the cerebellum [12]. It was observed that while the Keap1-
inhibiting Nrf2 activator tBHQ induced ARE-containing genes
GSTP1 and NQO1 in astrocytes, cerebellar granule neurons failed
to respond. The authors also noted that basal expression of these
genes was elevated in astrocytes compared to neurons [12],
making it unlikely that the neuronal pathway was unresponsive
due to being maximally active. Studies involving biolistic trans-
fection of an ARE-reporter into coronal cortical slices also revealed
highly preferential ARE reporter activity in astrocytes over neurons
[13], and an astrocyte-focused response to both tBHQ and sulfor-
aphane [11]. A potential explanation for lower neuronal Nrf2-ARE
pathway activity was provided by the observation that cortical
astrocytes express more Nrf2 protein basally than levels found in
neuronally-enriched cultures [10]. The authors’ microarray study
pointed to around 30-fold lower expression at the mRNA as well
[10]. This difference was all the more remarkable given that the
authors estimated that around 10% of neuronally-enriched cul-
tures were astrocytes. Later qPCR studies by ourselves and others
employing near-astrocyte free neuronal cultures corroborated this
differential: cortical neurons were found to express approximately
100–1000-fold less Nrf2 than astrocytes [14,15]. As if this were not
enough to limit neuronal Nrf2 activity, neurons also have a greater
capacity to promote degradation of what little Nrf2 is expressed,
by possessing higher Cul3-dependent Nrf2 degradation capacity
than astrocytes [15]. Consistent with all this, our lab observed no
transcriptional response of neurons to either small molecule ac-
tivators of Nrf2 (e.g. tBHQ) or to genetic activation of the pathway
(Keap1 deﬁciency). The molecular basis for Nrf2 gene repression in
neurons appears to be epigenetic in nature: neurons exhibit far
lower levels of Nrf2 promoter histone H3 acetylation than astro-
cytes [14]. The process of Nrf2 gene repression takes place early in
development: while Nrf2 expression and pathway activity are on a
par with astrocytes at P0 in vivo and days-in-vitro (DIV) 2 in vitro,
repression of expression, and reduction of promoter H3 acetyla-
tion has taken place by DIV 9 [14].
The biological reason why Nrf2 is expressed so weakly in ma-
turing neurons may be that it promotes weaker antioxidant de-
fences to facilitate redox signaling involved in neuronal develop-
ment [16,17]. Despite ectopic expression of Nrf2 in neurons being
profoundly protective against oxidative insults [18], it retards
structural and electrophysiological maturation [14]. Ectopic ex-
pression of Nrf2 appears to suppress the activity of devel-
opmentally important signaling pathways (JNK and Wnt) whose
activity is promoted by redox signaling [19–22]. Nrf2 activity re-
stricts this signaling by providing a strong cellular redox buffer,
preventing redox-dependent potentiation of these pathways [14].
In contrast, astrocytes evidently develop ﬁne whilst expressing
high levels of Nrf2, suggesting that the signaling pathways in-
volved in their maturation (which remain incompletely under-
stood [23]) may be less sensitive to redox status.
Despite the brake that Nrf2 puts on neuronal development, it
remains an open question as to whether re-activation of the Nrf2pathway once neurons have matured, may be a useful way of
boosting neuronal antioxidant defences. De-repression of the Nrf2
promoter can be achieved partly by treatment with a histone
deacetylase inhibitor [14], which, in combination with a Keap1-
inhibiting Nrf2 activator, can modestly induce Nrf2 target genes in
neurons [14]. Of note, enone-type electrophilic Keap1 inhibitors
curcumin and NEPP11 are reported to induce Nrf2 target gene
expression in neurons, unlike classical activators such as tBHQ
[24,25]. It is possible that these properties are due to curcumin’s
capacity as an epigenetic regulator as well as a Keap1 inhibitor
[26].
3. Weak Nrf2 activity in neurons means a reliance on astrocytes
Neurons in isolation have long been known to have limited
intrinsic antioxidant defences: they express relatively low levels of
catalase and do not contain high levels of GSH [1]. This is likely to
be due in part to their very low basal Nrf2 pathway activity, since
both catalase as well as key GSH biosynthetic and recycling en-
zyme genes are all controlled by Nrf2. Indeed, cortical neuronal
expression of Cat and Gclc (Υ-glutamate-cysteine ligase catalytic
subunit) are both far lower than that in astrocytes, and unlike
astrocytes, expression levels are not reduced by Nrf2-deﬁciency
[14]. Consistent with this, astrocytes are more resistant to oxida-
tive insults than isolated neurons, and unlike neurons their vul-
nerability is increased by Nrf2-deﬁciency [14].
Neurons are metabolically highly active, and consume large
amounts of ATP simply to maintain their resting membrane po-
tential. Neurons have relatively low glycolytic capacity and limited
scope to upregulate it upon increased energy demand [27]. As
such, ATP production is met largely through mitochondrial oxi-
dative phosphorylation [28], with astrocyte-derived lactate a po-
tentially important source of oxidizable substrate [29]. A by-pro-
duct of this dependency on oxidative phosphorylation however, is
ROS generation. There is evidence that even in well-coupled mi-
tochondria, ROS production does occur and correlates well with
the rate of electron transfer through the various complexes [30–
34]. Moreover, there is considerable evidence that elevated activity
leads to an increase in mitochondrial metabolism [35] and in-
creased mitochondrial ROS production, as well as ROS from non-
mitochondrial sources such as activity-inducible enzymatic sour-
ces like NADPH oxidase [30,36–40]. Thus, the high and variable
metabolic in neurons would appear to indicate a high requirement
for intrinsic antioxidant defences.
Nevertheless, despite their relatively low intrinsic antioxidant
defences, it is self-evident that post-mitotic central neurons sur-
vive and are functional for many decades. The explanation for this
apparent paradox is that neurons receive strong antioxidant sup-
port from surrounding glial cells, particularly astrocytes [1,41].
Astrocytes have a high capacity for the production and storage of
GSH, and release it into the extracellular medium in a manner that
is increased in response to oxidative stress, via the transporter
multidrug resistance protein 1 [1,42]. This GSH is broken down
extracellularly and cysteine-containing products taken up by
neurons and used to synthesize their own GSH [1,10,41,43]. Thus,
astrocytes play a key role in providing to neurons the basic
building blocks for GSH synthesis. Indeed, this whole process is
controlled by Nrf2 and induction of it appears to be a major me-
chanism by which astrocytic Nrf2 activation protects nearby
neurons, including human neurons [10,41,44,45].
Moreover, since oxidative stress also induces Nrf2-dependent
gene expression in astrocytes, including GSH pathway genes
[46,47], the capacity of astrocytes to provide neuronal support is
also homeostatically regulated. Another signal that can activate
astrocytic Nrf2 is chronic activation of astrocytic NMDA receptors,
a Ca2þ-permanent subtype of ionotropic glutamate receptor [15].
P.S. Baxter, G.E. Hardingham / Free Radical Biology and Medicine 100 (2016) 147–152 149Application of NMDA directly to astrocytes triggers Cdk5-mediated
Nrf2 phosphorylation and induction of Nrf2-dependent gene ex-
pression with the capacity to confer neuroprotection on nearby
neurons [15]. Since both oxidative stress, and chronically elevated
levels of ambient glutamate are both hall-marks of excitotoxic
disorders such as ischemia, both pathways may be involved in the
stress-induced activation of astrocytic Nrf2 that underlies some of
the neuroprotective effects of ischemic preconditioning [46–48].
Of note, the developmental repression of Nrf2 in neurons roughly
coincides with the onset of astrogliogenesis [14]. It is tempting to
speculate that developing neurons require functional Nrf2-medi-
ated antioxidant defences until there are sufﬁcient astrocytes in
the brain to provide external antioxidant support.
The demonstrably potent capacity of astrocytes to confer non
cell-autonomous neuroprotection against oxidative insults points
to the translational potential of small molecule Nrf2 activators.
Indeed, there exists a wide range of these which have shown
neuroprotective effects in variety of models of acute and chronic
neurological disorders, including stroke, and Alzheimer’s, Parkin-
son’s and Huntington’s diseases, as well as MS [49–51]. Note that
proof that the effects are mediated by astrocytes is currently
lacking and would require (for example) trials in mice with a
conditional deletion of Nrf2 in astrocytes.
Clear proof that astrocyte-driven Nrf2 activity is sufﬁcient to
confer neuroprotection in vivo has however been provided
through the generation of transgenic mice over-expressing Nrf2
speciﬁcally in astrocytes, and tested against models of a variety of
neurological and neurodegenerative disorders including Parkin-
son’s disease, Huntington’s disease, Alexander disease and ALS
[50,52–55]. It is worth noting that the exact mechanism of neu-
roprotection is unclear in these models. While it could be the
aforementioned astrocyte-derived GSH release, other potential
mechanisms also exist, such as maintenance of astrocyte health
and function, or preventing reactive astrogliogenesis. Never-
theless, targeting Nrf2 offers a promising therapeutic strategy
against neurodegenerative disorders associated with oxidative
stress [51], and potentially psychiatric ones too [56]. Such an ap-
proach of targeting endogenous gene expression programs is
conceptually different to classical small molecule antioxidant
therapies which have met with limited success in the clinic [57].
4. Dynamic regulation of neurons’ own antioxidant defences
Although the astrocytic supply of precursors for GSH synthesis
to neurons represents a key factor in enabling neurons to neu-
tralize ROS, it is not the only determinant. Neurons must be able to
use these precursors to synthesize GSH, as well as possess the
systems to utilize and recycle GSH, as well express other important
intrinsic antioxidant systems such as those based around thior-
edoxin and peroxiredoxins [58,59]. For example, in neurons where
the GSH biosynthetic enzyme gene Gclc was knocked down, as-
trocyte-derived GSH precursors are unable to confer their normal
protection [60]. Both the catalytic (Gclc) and modiﬁer (Gclm)
genes of GCL are Nrf2 target genes, as are other genes in the GSH
system such as glutathione reductase, and several glutathione
peroxidases [3]. However, since neurons do not possess robust
levels of Nrf2 they lack the ability to homeostatically regulate GSH
system gene expression this pathway via oxidative stress-induced
Nrf2 activation.
Interestingly, however, many GSH pathway genes and other
known Nrf2-regulated antioxidant genes such as Gclc, Gsr, Srxn1
and xCT are dynamically regulated in neurons by synaptic activity
[61–63]. At face value this makes sense, since the process of sy-
naptic activity and action potential ﬁring is energetically ex-
pensive, placing further ATP demands on the neuron which is met
by increased metabolic activity [64,65] and associated increasedROS production [30,36–39]. Consistent with this, increased sy-
naptic activity causes an immediate increase in GSH utilization
[66], unsustainable unless production can be increased to counter-
balance this increased demand. By inducing key GSH system
genes, synaptic activity increases the capacity of neurons to syn-
thesize, utilize and recycle GSH [62]. Thus, it could be that the
coordinated control of antioxidant genes by synaptic activity re-
presents a homeostatic control that helps to match intrinsic anti-
oxidant defence system capacity to the demands of an active
neuron. Mechanistically, neuronal activity regulates these known
Nrf2 target genes independent of Nrf2 [67], targeting activity-re-
sponsive transcription factors that also regulate these genes which
include ATF4 in the case of xCT [63], and AP-1 in the case of Srxn1
[61]. Indeed, an activity-responsive AP-1 binding site is actually
embedded within the functional ARE of the Srxn1 promoter [68],
something that is observed in a variety of Nrf2 target genes [69].
Ca2þ signaling, particularly through the NMDA receptor subtype
of ionotropic glutamate receptors, is a major mediator of activity-
dependent regulation of these antioxidant genes [61,62]. Indeed,
NMDA receptor blockade in vivo causes a reduction in brain Gclc
expression, GCL activity and GSH levels [62]. Moreover, this
blockade is associated with neurodegeneration which can be
ameliorated by supplying the brain with a cell-permeable form of
gamma-glutamyl-cysteine, the product of GCL catalysis [62]. Thus,
in the absence of a signiﬁcantly activatable Nrf2 pathway, the ac-
tivity-dependent regulation of antioxidant genes may represent an
important homeostatic regulator of a neuron’s intrinsic anti-
oxidant systems. Conceptually, this form of activity-dependent
homeostasis draws parallels with others, such as homeostatic
plasticity of synaptic strength, intrinsic excitability or circuit
structure [70–72].
5. Neuron-astrocyte cooperation to promote neuroprotection
A consequence of neuronal antioxidant genes being activity-
responsive is that synaptic activity can increase the capacity of
neurons to utilize the support provided by astrocytes. In other
words, while astrocytes are an important source of cysteine-
containing precursors that neurons take up and use to make their
own GSH, by increasing the GSH biosynthetic capacity of neurons,
neuronal activity makes them better able to use these astrocyte
cysteine-containing precursors to boost their intrinsic defences. As
described above, astrocytic support is under control of the Nrf2
pathway. Thus, while the activation of astrocytic Nrf2, and the
induction of synaptic activity, are separately neuroprotective,
combined they have an additive effect on the resistance of neurons
to oxidative insults [62]. The cooperative nature of the interaction
is depicted in Fig. 1.
One outstanding question, however, surrounds whether the
inﬂuence of synaptic activity on antioxidant gene expression is
limited to neurons. As noted above, exogenous activation of as-
trocytic NMDA receptors can activate Nrf2, raising the possibility
that neuronal glutamate release could control astrocytic Nrf2 [15].
Indeed, a recent study reported that stimuli that promote synaptic
activity, or neuronal depolarization, increase nuclear accumulation
of Nrf2 in astrocytes, raising the possibility that synaptic activity
controls the astrocytic Nrf2 pathway [73]. The consequences of
this for astrocytic Nrf2 target gene induction were not entirely
clear in the study, however, because the authors studied expres-
sion of these genes in a mixed population of neurons and astro-
cytes, meaning that the cell-type where they were being induced
was unclear. This is particularly relevant because (as stated above)
neuronal activity also induces known Nrf2 target genes in the
neurons themselves, independently of Nrf2 [67]. While we have
not observed astrocytic Nrf2 increases in response to neuronal
activity [67], we cannot rule out the possibility that it does happen
Fig. 1. Astrocytes and neuronal activity play distinct, cooperative roles in neuronal redox homeostasis. Astrocytes respond to mild oxidative stress and other inducers of the
Nrf2 pathway by turning on a program of Nrf2-mediated antioxidant gene expression, with consequent synthesis of GSH. GSH is exported via Mrp1 and degraded (by Ggt1),
with one or more degradation products taken up by neurons and fed into their own GSH biosynthesis pathway. Thus, while astrocytes provided support in providing the
building blocks for GSH production, neurons still require the capacity to make use of these raw materials. This capacity is controlled by synaptic activity-induced signaling
pathways, via the transcriptional control of a number of key genes involved in GSH synthesis, peroxidation and recycling.
This increased capacity may be a homeostatic response, since synaptic activity is metabolically expensive and can lead to increased ROS production both from mitochondrial
sources and Ca2þ dependent NADPH oxidase.
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underlines the fact that the general issue of astrocytic gene reg-
ulation by neuronal synaptic activity is one that requires further
investigation. While the mechanisms and consequences of activ-
ity-dependent gene expression in neurons have been the topic of
hundreds of papers over the past 30 years [74,75], little is known
about whether, or to what extent, neuronal activity inﬂuences the
transcriptome of surrounding glial cells, including astrocytes. Gi-
ven the intimate metabolic and functional coupling between
neurons and astrocytes [28], a clearer understanding of the me-
chanisms and consequences of reciprocal signaling between these
two cell types is needed. For studying gene regulation, this will
require neuronal activity to be induced in a mixed neuronal/as-
trocytic co-culture, followed by separation techniques that allow
the two transcriptomes to be distinguished. Unfortunately, physi-
cal separation prior to stimulation (e.g. astrocytes and neurons
separated using trans-well inserts) is not ideal because astrocytic
morphology and function in the absence of neurons is different to
that found in vivo [23,76]. More broadly, a greater understanding
of reciprocal interactions between all cell types within the neuro-
glial unit is required to gain a full picture of brain redox home-
ostasis. ROS do not simply damage neurons, but disrupt white
matter integrity, as well as push microglia towards pro-in-
ﬂammatory phenotypes. Indeed, Nrf2 mRNA expression in mi-
croglia is even higher than in astrocytes [77], pointing to an im-
portant regulatory role in this cell type too. The coming years will
likely uncover new homeostatic mechanisms the help maintain
the brain’s redox balance over a lifetime.Acknowledgements
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